The ubiquitin-proteasome pathway an emerging anticancer strategy for therapeutics: a patent analysis

• Published in: Recent patents on anti-cancer drug discovery Vol. 10; no. 2; p. 201
• Main Authors: Jain, Chakresh K, Arora, Shivam, Khanna, Aparna, Gupta, Money, Wadhwa, Gulshan, Sharma, Sanjeev K
• Format: Journal Article
• Language: English
• Published: United Arab Emirates 01.01.2015
• Subjects: Antineoplastic Agents - pharmacology; Apoptosis - drug effects; Drug Design; Humans; Molecular Targeted Therapy; Neoplasms - diagnosis; Neoplasms - drug therapy; Neoplasms - pathology; Patents as Topic; Proteasome Endopeptidase Complex - metabolism; TNF-Related Apoptosis-Inducing Ligand - metabolism; Ubiquitin - metabolism
• ISSN: 2212-3970
• DOI: 10.2174/1574892810666150416111213

The degradation of intracellular proteins is targeted by ubiquitin via non-lysosomal proteolytic pathway in the cell system. These ubiquitin molecules have been found to be conserved from yeast to humans. Ubiquitin proteasome machinery utilises ATP and other mechanisms for degrading proteins of cytosol as well as nucleus. This process of ubiquitination is regulated by activating the E3 enzyme ligase, involved in phosphorylation. In humans, proteins which regulate the cell cycle are controlled by ubiquitin; therefore the ubiquitin-proteasome pathway can be targeted for novel anti-cancer strategies. Dysregulation of the components of the ubiquitin system has been linked to many diseases like cancer and inflammation. The primary triggering mechanism (apoptosis) of these diseases can also be induced when TNF-related apoptosis-inducing ligand (TRAIL) binds to its specific receptor DR4 and DR5. In this review, the emerging prospects and importance of ubiquitin proteasome pathway as an evolving anticancer strategy have been discussed. Current challenges in the field of drug discovery have also been discussed on the basis of recent patents on cancer diagnosis and therapeutics.